LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

James Spargo | May 15, 2023 | News story | Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology 

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license agreement for a preclinical stage antibody drug conjugate (ADC).

LM-305 targets G protein-coupled receptor, class C, group 5, member D (GPRC5D). It consists of an anti-GRPC5D monoclonal antibody, a protease-degradable linker and a cytotoxic payload monomethyl auristatin E (MMAE). It is indicated for us in patients with multiple myeloma.

Within the agreement, AstraZeneca will be granted full exclusive global license to research, develop and commercialise LM-305. LaNova will be eligible for upfront and near-term payments of up to $55m, as well as additional development and commercial milestone payments of up to $545m and tiered royalties on net sales.

Dr Crystal Qin, founder, chairman and CEO of LaNova Medicines commented: “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca. With the potential to become a first-in-class GPRC5D-directed ADC for multiple myeloma, LM-305 exemplifies our innovative and robust platform for ADC development. This agreement is further recognition of our exceptional pipeline assets and R&D capabilities. We are confident that AstraZeneca is the ideal company to advance LM-305 for the betterment of patients globally.”

Nina Shah, global head of multiple myeloma, Haematology R&D at AstraZeneca, said: “We are pleased to have the opportunity to advance the development of LM-305, a novel GPRC5D-targeting ADC, as a potential new treatment option for relapsed/refractory multiple myeloma. LM-305 advances our leadership in ADCs and enriches our growing Haematology pipeline, helping us deliver against our broader ambition to transform clinical outcomes for patients living with blood cancers.”

James Spargo

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after …

Lonza to acquire Synaffix to strengthen ADC development

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …

Latest content